Global Ebola Preparedness in 2026: Progress, Gaps, and What Comes Next
Fifty years after Ebola's discovery, how well-prepared is the world for major Ebola outbreaks? This analysis assesses progress in vaccines, treatments, surveillance, and health systems — and identifies what remains dangerously insufficient.
Fifty Years of Ebola, and Where We Stand
Ebola was first identified in 1976. In the half-century since, it has caused over 40 outbreaks, infected more than 40,000 people, and killed more than 20,000. It remains, as of 2026, an active threat: an ongoing outbreak in North Kivu, DRC, and a surveillance system that detects new spillovers every few years.
The world is, without question, better prepared for Ebola in 2026 than it was in 2014. Approved vaccines exist. Approved treatments exist. Digital contact tracing platforms work. WHO has a dedicated Health Emergencies Programme.
But preparedness is not a binary state. And the 2026 outbreak is demonstrating, in real time, that significant gaps remain — some technical, some structural, some political.
What Has Improved Since 2014
1. Approved Vaccines
Before 2014: no approved Ebola vaccines.
In 2026: two approved vaccines for Zaire ebolavirus.
rVSV-ZEBOV (Ervebo): FDA/EMA-approved single-dose vaccine with ~97% field effectiveness. Deployed in DRC since 2018. In 2026, ring vaccination with rVSV-ZEBOV is standard in all Zaire ebolavirus outbreaks in DRC.
Ad26.ZEBOV/MVA (Zabdeno + Mvabea): EMA-approved two-dose regimen for prophylactic protection of healthcare workers in endemic areas. Provides durable immunity appropriate for routine pre-exposure vaccination.
2. Approved Treatments
Before 2014: no approved Ebola treatments.
In 2026: two approved monoclonal antibody treatments for Zaire ebolavirus.
Inmazeb (REGN-EB3) and Ebanga (mAb114): Both FDA-approved in 2020. Real-world data from DRC shows substantially reduced mortality (from ~70% untreated to ~35% with treatment) in patients receiving these agents.
3. Digital Contact Tracing
Go.Data (WHO’s open-source contact tracing platform) is deployed in all current DRC Ebola responses. It enables:
- Real-time contact registration and follow-up tracking
- Geographic mapping of transmission chains
- Alert generation for overdue follow-up visits
- Cross-border data sharing protocols
This represents a fundamental improvement from paper-based systems used in 2014.
4. WHO Health Emergencies Programme
Created in 2016 after the 2014 response failures, the WHO Health Emergencies Programme (WHE) provides:
- A Contingency Fund for Emergencies (CFE) with $100M reserve
- Rapid deployment capacity (within 24–72 hours of alert)
- Incident Management System framework
- GOARN (Global Outbreak Alert and Response Network) coordination
5. International Health Regulations and JEE Process
The Joint External Evaluation (JEE) process — a voluntary assessment of national health security capacities under the International Health Regulations — has now been completed by over 100 countries. These assessments provide baselines for national capacity development.
Current Gaps: Where Preparedness Is Still Insufficient
Gap 1: The Sudan Ebolavirus Problem
All approved vaccines and treatments target Zaire ebolavirus only. For Sudan ebolavirus — which causes outbreaks in Uganda every few years — the world has no approved countermeasure.
The 2022 Uganda outbreak killed 55 people with no vaccine or specific treatment. The next Sudan ebolavirus outbreak will face the same situation unless Phase 2/3 trials of the ChAd3-Sudan vaccine complete successfully and EUA frameworks are established in advance.
Current status: ChAd3-Sudan in Phase 2 trials. CEPI funding active. No EUA framework pre-negotiated. Timeline for approval: potentially 2027–2030 if no major outbreak accelerates process.
Gap 2: Health System Infrastructure in Endemic Regions
Despite 50 years of Ebola outbreaks, the countries most affected by Ebola — DRC, Uganda, Guinea — remain among the world’s most health-system-fragile. DRC has:
- Approximately 0.3 physicians per 1,000 population (vs. WHO target of 4.45)
- Fewer than 4,000 registered nurses for a population of 100 million+
- Healthcare facilities in eastern DRC that operate without reliable electricity, running water, or oxygen
The tools available for Ebola response are only useful if a health system exists to deploy them. A vaccine sitting in a cold chain in Kinshasa cannot protect a patient in Rutshuru if there are no healthcare workers to administer it and no facility to provide post-vaccination monitoring.
Investment gap: Bilateral aid to health systems in DRC has increased since 2016 but remains far below what is needed to build sustainable infrastructure.
Gap 3: Conflict Zone Response Capability
The DRC eastern provinces have been in a state of chronic armed conflict for 30 years. Response teams cannot safely access all affected areas. Surveillance is blind in conflict zones. ETCs in affected areas face destruction.
No international health framework has adequately solved the challenge of outbreak response in active conflict — the intersection of health security and military/political security remains a critical gap. The World Health Assembly’s 2016 Resolution on Health in Armed Conflict was aspirational; its operational implementation remains weak.
Gap 4: Community Trust Infrastructure
Effective Ebola response requires community trust. Building community trust requires sustained investment in community health workers, local ownership of health systems, and long-term relationship building.
This investment is consistently underfunded because:
- It produces slow, diffuse benefits (reduced outbreak severity when outbreaks occur)
- It requires recurrent funding, not one-time project grants
- Its results are hard to measure and attribute
In practice, community engagement is “activated” at outbreak declaration and wound down at outbreak end — the opposite of what is needed.
Gap 5: Vaccine Cold Chain Limitations
rVSV-ZEBOV requires storage at -60°C to -80°C — ultra-cold chain conditions that are challenging to maintain in tropical, low-infrastructure settings. Cold chain breaks lead to vaccine degradation and reduced effectiveness.
Thermostable vaccine formulations are in development but not yet licensed for rVSV-ZEBOV. The Janssen Ad26/MVA regimen has better cold chain stability (standard 2–8°C) but requires two doses 56 days apart — not practical for emergency ring vaccination.
Gap 6: Financing Models for Epidemic Preparedness
CEPI (Coalition for Epidemic Preparedness Innovations) has improved pipeline financing for vaccine candidates. But the full-cycle financing model — from research to stockpile to deployment — remains incomplete:
- Stockpiles of approved vaccines and treatments are limited
- Pre-negotiated purchase agreements don’t cover all likely scenarios
- Funding for outbreak response fluctuates based on donor attention (high during outbreaks, declining rapidly post-declaration)
The 100 Days Mission (producing validated vaccines, diagnostics, and treatments within 100 days of pathogen identification) adopted by G7 in 2022 remains aspirational — no country or institution has demonstrated this capability under realistic conditions.
Gap 7: Pandemic Agreement Gaps
The WHO Pandemic Agreement (formerly Pandemic Treaty) negotiations concluded in 2024 but contain limited binding commitments specifically relevant to Ebola-type outbreaks in low-income endemic countries. The agreement focuses primarily on influenza pandemic preparedness, reflecting the political interests of high-income countries.
Key Metrics for Assessing Preparedness
| Indicator | 2014 Baseline | 2026 Status | Target |
|---|---|---|---|
| Approved Zaire ebolavirus vaccine | None | 2 (Ervebo, Zabdeno/Mvabea) | Multi-strain coverage |
| Approved Zaire ebolavirus treatment | None | 2 (Inmazeb, Ebanga) | Sudan/Bundibugyo coverage |
| Countries with JEE completed | <20 | >100 | 194 (all WHO members) |
| DRC outbreak-to-ring-vaccination lag | N/A (no vaccine) | 3–7 days | <3 days |
| Sudan vaccine status | None | Phase 2 trials | Approved + stockpiled |
What Comes Next
The most important investments for Ebola preparedness in the next decade:
- Accelerate Sudan and pan-ebolavirus vaccine approvals — including pre-negotiated EUA frameworks
- Establish regional vaccine stockpiles in Africa (not dependent on European/US cold chain logistics)
- Fund sustainable community health worker programs in endemic countries
- Support DRC health system strengthening — particularly in eastern provinces
- Develop thermostable formulations of rVSV-ZEBOV for extended cold-chain independence
- Create standing Ebola-focused GOARN response capacity deployable within 48 hours to any outbreak
The current 2026 DRC outbreak will end. The next one will follow. Whether that next outbreak kills dozens or thousands will depend on how seriously the world takes the gaps that remain — not during the outbreak, but between them.
EbolaMap tracks the current DRC outbreak in real time. View our live map and latest situation reports for the most current outbreak data.